WebApr 20, 2024 · Aytu BioScience Signs Exclusive Global License with Cedars-Sinai for Potential Coronavirus Treatment. Led by Mark Pimentel, MD, the research team of the … WebApr 24, 2024 · The company believes the Healight platform technology has the potential to positively impact outcomes for critically ill patients infected with coronavirus and severe respiratory infections. The company licensed exclusive worldwide rights to the technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications. Patents have …
Aytu BioScience Signs Exclusive Global License with Cedars-Sinai …
WebJun 3, 2024 · ENGLEWOOD, CO/ ACCESSWIRE/ June 3, 2024/ Aytu BioScience, Inc., a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today ... WebLed by Mark Pimentel, MD, the research team of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai has been developing the patent-pending … knowledge and power
Aytu BioScience Signs Development Agreement with Sterling …
WebApr 20, 2024 · Cedars-Sinai-Developed ‘Healight' Medical Device Platform Technology Being Studied as a Potential First-in-Class COVID-19 Treatment. Conference Call … WebSep 27, 2024 · Initiation of Healight randomized, sham-controlled study planned near-term; recently published positive and validating data for UV-A light technology. platform. … WebOct 6, 2024 · Aytu has also licensed the Healight™ Platform Technology. Healight is a pre-clinical investigational device being studied as a potential treatment for COVID-19 in severely ill, intubated patients and potentially other respiratory illnesses. Aytu also operates a consumer health subsidiary, Innovus Pharmaceuticals, Inc. ("Innovus"), a specialty ... knowledge and power selling price